E-mail this page Printer Friendly Version RSS E-mail Alerts View contacts Download Financial Tear Sheet 

2016 Press Releases

This section of the website contains information that should be considered accurate as of the date presented. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Quest Diagnostics is not obligated to update the information contained in this section of the website.

Keyword Search
 
2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006
DateTitle 
04/28/16Zika Test from Quest Diagnostics Authorized by the FDA for Emergency Use
First Test from a Commercial Lab to Receive Emergency Use Authorization for Testing Patients in the United States, including Puerto Rico, for Zika Infection MADISON, N.J., April 28, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has received a U.S. Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for the Zika Virus RNA Qualitative Real-Time RT-PCR test (Zika RT-PCR test). The te... 
Printer Friendly Version
04/21/16Quest Diagnostics Reports First Quarter 2016 Financial Results
- Q1 2016 revenues of $1.86 billion grew 3.6% on an equivalent basis and 1.3% on a reported basis - Diagnostic Information Services revenues increased 3.8% from a year ago - Adjusted diluted EPS excluding amortization of $1.12, up 6.7% from 2015 - Reported diluted EPS of $0.70, up 67% from 2015 MADISON, N.J., April 21, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that for the first ... 
Printer Friendly Version
04/15/16New Diagnostic Pathways Could Improve Dementia Diagnosis, According to Consensus Statements to Be Presented at the American Academy of Neurology Annual Meeting
Quest Diagnostics and UCSF will also present novel research on improving the quality and reducing the costs of dementia care MADISON, N.J., April 15, 2016 /PRNewswire/ -- A tiered diagnostic approach that incorporates clinical, imaging and laboratory data may help physicians more efficiently screen for neurodegenerative disorders such as dementia, according to the consensus of a multi-disciplinary panel of experts. The consensus statement is among eight presentations developed with the part... 
Printer Friendly Version
04/14/16Quest Launches New Hepatitis C Virus Test Capabilities for Recently FDA-approved Antiviral Therapies
MADISON, N.J., April 14, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has expanded its chronic hepatitis C virus (HCV) test services to include new capabilities to help physicians identify or predict resistance to several HCV therapies, including the recently FDA-approved Zepatier™, from Merck, and Daklinza™, from Bristol-Myers Squibb. The new services enhance the ability of physicians to determ... 
Printer Friendly Version
04/07/16Quest Diagnostics To Release First Quarter 2016 Financial Results On April 21
MADISON, N.J., April 7, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report first quarter 2016 results on Thursday, April 21, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 773-681-5898, passcode 3214469. The company sugg... 
Printer Friendly Version
03/30/16DiaSorin To Acquire Focus Diagnostics' Molecular And Immunoassay Product Business From Quest Diagnostics, Significantly Advancing Its Presence In The Molecular Diagnostic Market
- Focus Diagnostics' unique Simplexa™ platform and products to allow DiaSorin to quickly enter the molecular segment; - DiaSorin will strengthen its offering in the US market accessing approximately 200 hospitals served today by Focus, and will leverage its commercial presence worldwide to distribute the Focus products in markets today under served in Europe and Asia; - The cash transaction, valued at $300 million, is expected to be immediately accretive to DiaSorin's ongoing earnings per ... 
Printer Friendly Version
03/29/16Quest Diagnostics Marlborough Lab Earns LEED Green Building Certification
MADISON, N.J., March 29, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that its state of the art clinical laboratory in Marlborough, Mass., has achieved Leadership in Energy and Environmental Design (LEED) certification from  the U.S. Green Building Council. The 209,000 square foot lab serves as the hub for the New England area and hosts more than 1,000 employees. Environmentally friendly features ... 
Printer Friendly Version
03/29/16Quest Diagnostics Announces Early Tender Date Results of Cash Tender Offers for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 29, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the early tender results of its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 Notes" and... 
Printer Friendly Version
03/28/16Quest Diagnostics Announces Pricing of Cash Tender Offers for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 28, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today the determination of the pricing for its previously announced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 (the "2037 Notes") and 5.750% Senior Notes due 2040 (the "2040 N... 
Printer Friendly Version
03/15/16Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Combined Aggregate Principal Amount of Certain of its Outstanding Notes
MADISON, N.J., March 15, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced today that it has commenced cash tender offers (each, an "Offer" and, collectively, the "Offers") to purchase up to $200 million combined aggregate principal amount (the "Maximum Tender Amount") of its 6.950% Senior Notes due 2037 and 5.750% Senior Notes due 2040 (collectively, the "Notes"). The terms and conditions of the Offers are... 
Printer Friendly Version
03/09/16Quest Diagnostics To Speak At The Barclays Global Healthcare Conference
MADISON, N.J., March 9, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the Barclays Global Healthcare Conference in Miami.  Mark Guinan, the company's Senior Vice President and CFO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Thursday, March 17, 2016 at 10:45 a.m. Eastern Time. The presentation will be webcast l... 
Printer Friendly Version
02/29/16Quest Diagnostics Completes Acquisition of Clinical Laboratory Partners' Outreach Laboratory Service Business in Connecticut
MADISON, N.J. and HARTFORD, Conn., Feb. 29, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it has completed its previously announced acquisition of the outreach laboratory service business of Clinical Laboratory Partners (CLP), a wholly-owned subsidiary of Hartford HealthCare (HHC). HHC is an integrated health care system with five hospitals in Connecticut. Financial terms were not disclosed. With the acq... 
Printer Friendly Version
02/24/16Quest Diagnostics and Inovalon Bring Real-Time, Point-of-Care Analytics to HIMSS16 with Data Diagnostics™
Integrated with nearly 600 EHR platforms to align clinical management with quality, utilization and financial performance goals MADISON, N.J. and BOWIE, M.D., February 24, 2016 – Quest Diagnostics (NYSE: DGX) and Inovalon (Nasdaq: INOV) today announced they will showcase Data Diagnostics™, real-time analytics at the point of care, at HIMSS16, furthering the national roll-out of the solution. Based on one of healthcare’s largest datasets and integrated with nearly 600 electronic h... 
Printer Friendly Version
02/22/16Quest Diagnostics to Showcase Its Advanced Healthcare Information Technology Solutions at HIMSS16 Under its New Quanum™ Brand
The Quanum suite of healthcare information and technology solutions, based on Quest's industry leading dataset of 20 billion test results and national connectivity, help deliver better care and outcomes at lower costs MADISON, N.J., Feb. 22, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it will showcase its Quanum™ suite of healthcare information technology (HIT) solutions, including Data Diagnostics with... 
Printer Friendly Version
02/19/16Quest Diagnostics Named One of 2016 "World's Most Admired Companies" by Fortune Magazine
MADISON, N.J., Feb. 19, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced that it has been named one of the "World's Most Admired Companies" for 2016 by Fortune.  The annual Fortune "World's Most Admired Companies" survey ranked Quest Diagnostics third among 10 companies in the "Health Care: Pharmacy and Other Services" industry, a jump of two places from last year. Quest ranked in the top three in all of th... 
Printer Friendly Version
01/28/16Quest Diagnostics Reports Fourth Quarter And Full Year 2015 Financial Results; Provides Guidance For Full Year 2016; Increases Dividend 5% To $0.40 Per Quarter
-- Full year revenues grew 2% on an equivalent basis and 0.8% on a reported basis -- Full year adjusted diluted EPS excluding amortization of $4.77, up 6% versus prior year -- Full year reported diluted EPS of $4.87, up 29% versus prior year -- Fourth quarter revenues grew 0.6% on an equivalent basis versus 2014; down 1.8% on a reported basis versus 2014 -- Fourth quarter adjusted diluted EPS excluding amortization of $1.19, up 0.8% versus prior year -- Fourth quarter reported dil... 
Printer Friendly Version
01/25/16Quest Diagnostics Expands Dako's PD-L1 IHC 28-8 Complementary Test to Include Melanoma
Third offering in Quest's precision medicine menu for oncology immunotherapies MADISON, N.J., Jan. 25, 2016 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), the world's leading provider of diagnostic information services, today announced it will offer clinical laboratory testing using the PD-L1 IHC 28-8 pharmDx qualitative test from Dako, an Agilent Technologies company. Earlier today, Dako announced the U.S. Food and Drug Administration (FDA) approved the complementary in vitro diagnostic te... 
Printer Friendly Version
01/15/16Quest Diagnostics To Release Fourth Quarter And Full Year 2015 Financial Results On January 28
MADISON, N.J., Jan. 15, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it will report fourth quarter and full year 2015 results on Thursday, January 28, 2016, before the market opens. It will hold its quarterly conference call to discuss the results beginning at 8:30 a.m. Eastern Time on that day. The conference call can be accessed in listen-only mode by dialing 415-228-4961, passcode 3214469.... 
Printer Friendly Version
01/04/16Quest Diagnostics To Speak At The 34th Annual J.P. Morgan Healthcare Conference
MADISON, N.J., Jan. 4, 2016 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), the world's leading provider of diagnostic information services, announced that it is scheduled to speak at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco. Steve Rusckowski, the company's President and CEO, will discuss the company's vision, goals and five point strategy. The presentation is scheduled for Tuesday, January 12, 2016 at 7:30 p.m. Eastern Time. The presentation will be we... 
Printer Friendly Version